Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults.
The outcome of Helicobacter pylori infection was analyzed in 114 dyspeptic patients treated with triple-drug therapy including clarithromycin. Clarithromycin resistance (in 20.2% of our isolates) was mainly caused by an A2142G mutation in the 23S rRNA gene of H. pylori. H. pylori eradication was obtained in all patients with clarithromycin-susceptible isolates but not in any patients with clarithromycin-resistant isolates (P = 0.0001). Therefore, it would be useful to conduct H. pylori antimicrobial susceptibility testing of the first gastric biopsy culture before choosing the first three drugs for therapy of infected patients.
Lee
Jong Hwa
JH
Research Center for Gastroenterology, Dankook University College of Medicine, Cheonan, Choongnamdo, Republic of Korea.
Shin
Ji-Hyun
JH
Roe
Im Hwan
IH
Sohn
Seung Ghyu
SG
Lee
Jung Hun
JH
Kang
Geun Ho
GH
Lee
Han-Ki
HK
Jeong
Byeong Chul
BC
Lee
Sang Hee
SH
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017291:Clarithromycin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000235:genetics; D005260:Female; D020459:Genes, rRNA; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009154:Mutation; D010437:Peptic Ulcer / Q000382:microbiology; D012338:RNA, Ribosomal, 23S / Q000235:genetics; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D012338:RNA, Ribosomal, 23S; D017291:Clarithromycin